Search Bar & Filters
Found 32 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.
Actively Recruiting
Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in treating psychosis associated with Alzheimers Disease AD in people aged 55 to 90 years. This Phase 3 study compares KarXT to a placebo to see how well it helps reduce hallucinations and delusions in patients with mild to severe AD psychosis. The study measures changes using the Neuropsychiatric Inventory-Clinician NPI-C score focused on hallucinations and delusions. Participants receive either KarXT capsules at varying doses or placebo capsules in a randomized, double-blind manner. The treatment period lasts up to 14 weeks, during which researchers monitor symptoms and side effects. KarXT doses range from 202 mg up to 66.76.67 mg daily, assessing safety and efficacy compared to placebo. During the study, participants undergo assessments including clinical scales such as the NPI-C and the Clinical Global Impressions-Severity CGI-S scale. Caregiver distress and other behavioral symptoms are also evaluated. Researchers track changes from baseline to the end of treatment. The study includes safety monitoring and aims to understand KarXTs impact over the 14-week treatment period.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284 in patients experiencing agitation associated with Alzheimers dementia. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to understand how ITI-1284 affects agitation symptoms in this population. Participants receive either ITI-1284 at doses of 10 mg or 20 mg as a rapidly disintegrating tablet taken once daily under the tongue, or a matching placebo tablet taken the same way. The study uses a flexible-dose design and assigns participants randomly to one of the two groups. Treatment is administered daily during the trial. Throughout the study, participants agitation is measured using the Cohen-Mansfield Agitation Inventory total score at Week 12 as the primary outcome. Additional assessments include the Clinical Global Impression-Severity score at Week 12. Participants are monitored for safety and tolerability, and the study lasts until completion around December 2027.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of ITI-1284, a sublingual drug, compared with placebo in treating psychosis associated with Alzheimers disease. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 55 and older diagnosed with Alzheimers disease and psychosis. The study aims to improve understanding of how ITI-1284 may affect psychotic symptoms in this population. Participants will receive either ITI-1284 tablets at doses of 10 mg or 20 mg or matching placebo tablets, taken once daily by sublingual administration. The study uses a flexible-dose design and follows a parallel-group model with random assignment to the drug or placebo groups. Treatment and assessments are conducted over the study period, with primary measurement of psychosis symptoms at Week 6. Throughout the trial, participants will be monitored regularly for symptom changes using the BEHAVE-AD psychosis subscale and the Clinical Global Impression-Severity score. Cognitive function will be evaluated using the Mini-Mental State Examination. Safety and tolerability will be assessed continuously, and a designated caregiver will support participants. The total study duration extends through to December 2028, with primary outcomes assessed at 6 weeks.
Actively Recruiting
Researchers are investigating the safety and effectiveness of a new device called the Alleviant ALV1 System, designed to create an interatrial shunt for patients with heart failure and reduced ejection fraction HFrEF. This prospective, randomized, double-blind, sham-controlled trial involves multiple centers and aims to compare the outcomes of patients receiving this device to those undergoing a sham procedure. The study focuses on those with heart failure who have a left ventricular ejection fraction of 40% or less and are classified as NYHA class II, III, or ambulatory IV. Participants are randomly assigned to one of two groups. The treatment group undergoes cardiac imaging, femoral vein access, and receives the Alleviant ALV1 System device procedure to create the interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement but does not receive the device. The study uses a crossover design, allowing comparison between the treatment and sham procedures under double-blind conditions. Throughout the study, participants will be monitored for safety and efficacy, with cardiac imaging used to assess outcomes. The primary outcome is a composite endpoint measured at 12 months, which evaluates the overall impact of the device on heart failure. The trial is sponsored by Alleviant Medical, Inc. and will continue until December 2028. Participants can expect regular assessments and follow-up visits during the study period.
Actively Recruiting
Researchers are evaluating zenagamtide, an oral medication, to determine its safety and effectiveness in helping adults with excess body weight lose weight. This phase 3 clinical trial compares zenagamtide against a placebo to understand its impact as part of a treatment for overweight and obesity. The study involves participants aged 18 and older who will be randomly assigned to different treatment groups. Participants will receive either one of five dose levels of zenagamtide or a placebo, both taken orally once daily. These treatments are combined with a reduced-calorie diet and increased physical activity to support weight loss efforts. The study treatment period lasts up to 76 weeks, during which participants follow the lifestyle changes alongside the medication or placebo. Throughout the study, participants will be monitored regularly to assess changes in body weight as the primary outcome, alongside secondary measures like waist circumference and systolic blood pressure. Safety and adherence will also be tracked. The total participation duration extends up to about 76 weeks, with ongoing evaluations to understand the treatment effects over this timeframe.
Actively Recruiting
Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.
Actively Recruiting
The DISRUPT-AF Registry is an observational, prospective, multi-center study designed to collect real-world clinical data on the FARAPULSE Pulsed Field Ablation PFA System for treating atrial fibrillation AF. This study specifically focuses on a subset of patients from the DISRUPT AF Registry who participate in the BOUNCE-AF sub-study. The purpose is to gather experience and monitor outcomes after ablation treatment for AF. Participants in the BOUNCE-AF sub-study will wear the BodyGuardian device for monitoring at 6 months post-ablation, following the sites standard of care which typically includes monitoring at 6 and 12 months after the procedure. Both patients and clinical staff involved with the BodyGuardian device will be asked to complete surveys about their experience with the monitoring device. During the study, patients will be observed based on their routine care schedules, with data on BodyGuardian wear collected at 6 months. Clinical staff who consent will also provide feedback through surveys. The primary outcome is measured from enrollment until the end of BodyGuardian wear at 6 months. The total participation duration extends through the monitoring period, with follow-up assessments aligned to clinical practice.
1-10 of 32
1